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Abstract This literature review updates the reader on the new
studies regarding steroid therapy over the last year in stable
COPD and in exacerbations. In stable COPD, we critique the
2011 update and 2013 revision of the GOLD guidelines,
discuss why combining inhaled corticosteroids (ICS) with
long-acting beta-agonists (LABA) (ICS/LABA) is preferable
over LABA alone and review the literature for intraclass
differences, finding that the evidence does not clearly support
superiority of any particular ICS/LABA. We also address
other comparisons against ICS/LABA, including triple thera-
py. We briefly review which type of inhaler should be chosen.
For exacerbations, we report the REDUCE trial findings
favouring a 5-day course of systemic steroids, and other trials
addressing which steroid and route to use, including in an
intensive care setting. Lastly, the future lies in new anti-
inflammatories and re-phenotyping the heterogeneous amal-
gamation of COPD. A Spanish guideline recommends
distinguishing steroid-responsive eosinophilic exacerbators
from other phenotypes.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
disease characterised by chronic airflow limitation and
airways inflammation. It is a leading cause of morbidity
and mortality worldwide, and this is set only to in-
crease. A patient may present with dyspnoea, chronic
cough and sputum production, and a history of exposure
to risk factors such as smoking. The diagnosis, however,
is spirometric, with a post-bronchodilation forced expi-
ratory volume in one second (FEV1) to forced vital
capacity (FVC) ratio<0.70. The aim of COPD manage-
ment is to slow down the progression of the disease and
improve the patient’s quality of life [1•].
Corticosteroids are thought to decrease the chronic inflam-
mation in the bronchial tree, thereby improving obstructed
airflow.
Inhaled corticosteroids (ICS) in COPD are known to
improve symptoms, lung function, quality of life, and
reduce exacerbations. They do not, however, modify the
long-term decline in lung function nor mortality. Associ-
ated adverse effects are pneumonia, oral candidiasis,
hoarse voice, bruising, and some mixed evidence regard-
ing osteoporosis [1•]. There may be an increased risk of
TB and non-tuberculous mycobacterial infections (Sabroe
2013), but ICS may reduce the risk of lung cancer [2–4].
Combining ICS treatment with long-acting beta2-
agonists (LABA) seems to reduce mortality, despite in-
creasing risk of pneumonias, but have no other significant
adverse effects. Compared to the individual components,
ICS/LABA improves lung function and reduces exacerba-
tions even more in moderate to very severe COPD. [1•]
Therefore, ICS are now only recommended as combined
treatment, mostly with LABA, based on low spirometry
values (American College of Physicians, ACP), symptom
severity and risk of exacerbations (UK National Institute
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for Health and Care Excellence, NICE), or both (Global
Initiative for Chronic Obstructive Lung Disease, GOLD)
[5]. There have been some developments during the last
few years in the evidence for triple therapy (adding in an
additional drug, tiotropium, a long-acting anticholinergic/
antimuscarinic [LAMA]).
Long-term treatment with systemic steroids, however,
is associated with many adverse effects, especially steroid
myopathy [1•]. They are recommended as a short course
in the treatment of exacerbations of COPD because they
shorten recovery time and the length of hospital stay,
improve FEV1 and hypoxemia (PaO2), and reduce the
risk of early relapse and treatment failure. In this area
too, there have been some developments during the last
few years.
Aim & Structure
The aim of this review is to update the reader on the manage-
ment of COPD with steroids with new developments from
2013 onwards.
We will update the reader on the GOLD 2013 revision
and updated Cochrane reviews. We will review the indi-
cations and risks of inhaled steroids, which steroid or
combination is best to use, and which inhalers
(pressurised metered dose [pMDI], dry-powder [DPI]) to
choose. For oral steroids, we will recount important new
evidence on the duration of exacerbation treatment. Last-
ly, we will update the reader about new evidence regard-
ing corticosteroid treatment responsiveness.
Methods
We performed a Pubmed (MEDLINE) search with the search
terms:
("steroids" [MeSH Terms] AND "pulmonary disease,
chronic obstructive" [MeSH Terms]) OR (corticoste-
roid copd) OR (steroids copd)Filters:Publication date
from 2012/10/01
(Current as of 31/03/2014)
For head-to-head comparisons of inhaled steroids, we per-
formed searches of both Pubmed and ClinicalTrials.gov for
recent trials, using two of the following: “budesonide”,
“fluticasone” , “beclomet(h)asone” , “ciclesonide” ,
“mometasone”, “flusinolide”, “betametasone”, or “triamcino-
lone”, combined with “COPD”. (These latter searches are
current as of 17 January 2014.)
Stable COPD: inhaled corticosteroids
GOLD guidelines
2011 Update
GOLD attempt to provide international guidelines for the
management of COPD. A major update was produced in
2011, where it was felt that basing management decisions on
spirometric staging alone (stage 1, mild as FEV1≥80 % pre-
dicted; stage 2, moderate FEV1<80 % predicted; stage 3,
severe FEV1<50 % predicted; and stage 4, very severe
FEV1<30 % predicted) showed insufficient prediction of
disease severity. Instead, symptom scores, using the COPD
Assessment Test (CAT) and modified British Medical Re-
search Council questionnaire (mMRC), and exacerbation risk
prediction (using the spirometry staging or the past year’s
number of exacerbations) were recommended to divide pa-
tients in four GOLD groups. Groups A and B correspond to
low exacerbation risk, with few and more symptoms, respec-
tively. Groups C and D correspond to high risk (stages 3/4,
and/or≥2 exacerbations annually), with GOLD group C
denoting few symptoms (CAT<10 or mMRC grade 0 to 1),
and group D more symptoms (CAT≥10 or mMRC≥2) [1•].
Criticisms
During the last 3 years, the GOLD guidelines have been
criticised somewhat. Lee et al. [5] note that GOLD is
funded by pharmaceutical companies that make COPD
medications and that the board of directors, committee
members, and reviewers have ties to the industry. Further,
they note that there is no evidence that these guidelines
produce better outcomes than the aforementioned ACP or
NICE guidelines. Yawn [6] critiques that “the recom-
mended medication hierarchy relies on research evidence
from very short-term, 12-week studies and significant
expert opinion.” She further wondered why validated
primary care tools were left out in favour of the mMRC
and CAT. Jones et. al [7] considered the new classification
too complicated for primary care and were disappointed at
the lack of consultation with primary care members. Per-
haps the biggest criticism came from the COPDGene
prospective cohort study: across a population, there are
relatively few patients who correspond in the new group
C, and also differences in classification, depending on
whether the St George’s Respiratory Questionnaire
(SGRQ) (as a surrogate for CAT) or the mMRC scale is
used [8]. A Spanish cohort examining four scales (CAT,
mMRC, BODE, CCQ) reached the same conclusion [9].
The GOLD authors responded that the CAT and mMRC
were evidence-based, quick, and easy-to-use. They conceded,
however, that “…in 2011 there were no data concerning [CAT
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scale] equivalence with mMRC. These data are now available
and show the equivalence threshold for CAT ≥10 is mMRC
≥1 [not ≥2], something that might need to be addressed in
future GOLD updates." [10]
2013 Revision
February 2013 saw the “first update of the 2011 revised
report" [1•]. The CCQ (Clinical COPD Questionnaire) was
added to the CATand mMRC, with a cut-off of 0-1 for groups
A and C, and>1 for groups B and D.
There were some minor changes to the stable COPD treat-
ment hierarchy, and the most important change was that the
first line for group D now includes the option of triple therapy,
due to new evidence (see further below). Changes are outlined
in Table 1.
Reviewing the groups to which steroids are relevant –
GOLD recommends as first choice for group C a fixed com-
bination of ICS/LABA or a LAMA, with differentiation be-
tween these two choices difficult. Alternatives recommended
are a LABA+LAMA or ICS+LAMA (although there is no
evidence for this combination), as both LABAs and LAMAs
reduce exacerbations. Further alternatives are suggested in
cases of chronic bronchitis or low-resource settings.
For group D, ICS+LABA or ICS+LAMA is recommend-
ed, with some evidence for triple therapy (ICS+LABA+LA-
MA). It is the first thing to try as an alternative, with
phosphodiesterase-4 inhibitors (PDE-4I) to be added in cases
of chronic bronchitis, and more alternatives suggested if
LABAs are unacceptable choices.
ICS/LABA versus LABA
Inclusion criteria of randomised controlled trials (RCTs) are
often based on the guidelines preceding their protocol. The
difficulty with changing guidelines significantly is that one
has to review the old evidence for the applicability of their
patient populations.
Group C or D patients: ICS/LABA versus LABA
When group C or D patients present to clinicians, is GOLD
justified in recommending an ICS/LABA as opposed to a
LABA (indicated for group B)?
An updated version of the ICS/LABA versus LABA
Cochrane review was published in 2012, with a search current
as of November 2011 [11•]. The vast majority of the patients
in the 15 included trials (n=11,794 patients) had severe to
very severe COPD (group C or D). Reviewing the inclusion
criteria, at least the three biggest trials (48 % of n) had an
mMRC of 2 (or equivalent). Like the GOLD guidelines,
therefore, the evidence comes from group C, with preponder-
ance for group D. Four new studies were included since the
last version – four out of the top seven biggest in the review
(37 % of n) – but this had little impact on the conclusions.
Compared with LABA, the combination treatment was more
effective in improving health-related quality of life, dyspnoea,
symptoms, rescue medication use, and FEV1. There was low
quality evidence that the combination treatment reduced ex-
acerbation rates (rate ratio 0.76; 95 % CI 0.68 to 0.84),
downgraded because of inter-study heterogeneity and by high
withdrawal rates. In response to some criticism regarding the
reporting of exacerbations in trials with high drop-out rates
[12], a new odds ratio was reported for patients with at least
one exacerbation, also showing improvement in favour of
ICS/LABA (OR 0.83; 95 % CI 0.70 to 0.98). There was no
difference in mortality or hospitalisations. Importantly, how-
ever, there was an increased risk of pneumonia (OR 1.55;
95 % CI 1.20 to 2.01), which was not significantly different in
trials with different doses. This was deemed moderate quality
evidence, again due to the high withdrawal rate.
The evidence that ICS decrease the risk of exacerbations,
yet increase the chance of pneumonia is corroborated by the
2012 update of the ICS (alone) vs. placebo Cochrane review
[13]. As it also, however, found that there was no difference in
mortality, so there have been suggestions in the past that ICS
might increase all pneumonia events, but reduce severe
Table 1 Revised GOLD 2013 management of stable COPD. Differences with 2011 update in bold
GOLD group First choice Alternative choice (in random order)
A (low risk, less
symptoms)
SABA or SAMA LABA or LAMA or SABA+SAMA
B (low risk, more
symptoms)
LABA or LAMA LABA+LAMA
C (high risk, less
symptoms)
ICS/LABA or LAMA LABA+LAMA or LABA+PDE-4I or LAMA+PDE-4I
D (high risk, more
symptoms)
ICS with (LABA and/or
LAMA)
ICS/LABA+LAMA or ICS/LABA+PDE-4I or LABA+LAMA or LAMA+PDE-4I or
ICS+LAMA
SABA, short-acting beta-2 agonist (e.g. salbutamol, terbutaline). LABA, long-acting beta-2 agonists (formoterol, salmeterol; extra-long: indacaterol,
vilanterol). SAMA, short-acting anticholinergic (ipratropium, glycopyrronium, aclidium). LAMA, long-acting anticholinergic (tiotropium,
umeclidinium). ICS, inhaled corticosteroid (e.g. budesonide, fluticasone, beclometasone, mometasone). PDE-4I, phosphodiesterase-4 inhibitor (e.g.
roflumilast)
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pneumonias and their complications, as Almirall et al. [14]
explain. Their 1-year observational study found that ICS had
no impact on hospitalisation for community-acquired pneu-
monia when adjusting for severity, and had no association
with ICU admission, days-to-clinical recovery or mortality.
This is disputed by another publication from last year, a
claims-data analysis (data from 2006-2010). It found that
compared to no treatment with ICS, ICS use was associated
with a significant, potentially dose-related increase in risk of
pneumonia in patients with COPD. The authors defended the
methodology of using a non-RCT design, stating that this
association was unlikely to be down to more frequent use of
ICS in patients with exacerbations, as exacerbations are usu-
ally viral and that the article’s real-life population had more
comorbidities, reflecting real-life, and higher incidence of
pneumonia: "This suggests the possibility that the incidence
of ICS-associated pneumonia among non-selected patients
with COPD may be higher than reported in controlled clinical
trials." [15]
Another recent cohort study, however, with data from 1990
– 2005, followed up patients until 2007 or their first serious
pneumonia event. They did find that ICS were associated with
an increased risk of serious pneumonia by 69 %. The higher
risk was prolonged with long-term use and disappeared about
6 months after discontinuation. This risk was particularly
raised for fluticasone (RR 2.01) (also dose-related), much
higher than for budesonide (RR 1.17) [16].
This raises the question whether there are intraclass differ-
ences in the effects of steroids. A 2009 individual patient data
meta-analysis examining budesonide did not find an increase
in pneumonia risk for this steroid [17]. Returning to our ICS/
LABA vs. LABA question, the Nannini Cochrane review
[11•] included only studies with the fluticasone propionate
plus salmeterol (FP/S) and the more recent budesonide plus
formoterol (BUD/F) combination inhalers. They performed a
sub-analysis for these two separate products and found that
there were no significant differences in either exacerbations or
pneumonia. They did, however, find that candidiasis (OR
3.75) and upper respiratory infection (OR 1.32) were more
frequent in FP/S than salmeterol only. For BUD/F, candidiasis
adverse event data was not combined as the results were very
inconsistent.
A new Cochrane review has sought to address whether the
risk of pneumonia is increased in COPD when treated with
steroids (alone or in combination with LABA) [18]. It in-
cludes 43 studies, 26 of fluticasone (n=21,247) and 17 in-
volving budesonide (n=10,150). Fluticasone treatment had a
higher risk of serious pneumonias requiring hospital admis-
sion (OR 1.78, 95 % CI 1.50-2.12; high quality), and this
finding was not dose-related, or reduced when combined with
salmeterol or vilanterol. Budesonide also had this effect, but to
a lesser extent (OR 1.62, 95 % CI 1.00 to 2.62; moderate
quality), and this effect was dose-related. The only difference
the authors found when comparing monotherapy of
fluticasone with budesonide was an increased risk of any
pneumonia (including mild community cases) (OR 1.86,
95 % CI 1.04 – 3.34), but this is an indirect comparison, and
there were inconsistent diagnostic criteria for pneumonia in
the studies.
The third ICS/LABA combination product that is vying for
market approval in COPD is the beclometasone dipropionate/
formoterol (BDP/F) inhaler. A new Cochrane review was
published looking into the effect of BDP in COPD [19], and
includes the BDP/LABA vs. LABA comparison. In this re-
view arm, only one study was found (n=476, group C/D
patients) [20]. The review found improvements in lung func-
tion and use of rescue medication, which were probably not
clinically significant. No difference was found in pneumonia,
mortality, or exacerbations. There was some debate
concerning a significant increase in exacerbations leading to
hospitalisation, depending onwhether you accept the rationale
of the author’s post-hoc analysis. Interpretation of these find-
ings based on one study is difficult, and the review identified
an ongoing trial looking at BDP/F vs. F which could shed
more light on the matter (FORWARD study [21]).
Lastly, a new Cochrane network meta-analysis demonstrat-
ed that within the available evidence, ICS/LABA shows the
biggest improvements compared with placebo, followed by
LAMA or LABA, and then ICS alone, for both the SGRQ and
FEV1 values [22]. They did not analyse other clinically im-
portant outcomes such as mortality and exacerbations, quoting
two other meta-analyses on these instead: Dong et al. [23]
found that ICS/LABA had the lowest risk of mortality when
compared with placebo, tiotropium or LABA only, and a 2009
meta-analysis looking at exacerbations only, which found that
neither ICS or ICS/LABAwas more effective than each other
or LAMA [24].
Which inhaled corticosteroid?
The suggestion of differences between the available steroids
and steroid combination products begs the question of which




The best comparison of fluticasone propionate/salmeterol and
budesonide/formoterol is a 2011 indirect, systematic review of
RCTs of either FP/S or BUD/F, synthesised using the placebo
comparator as a common denominator, as “there were no head-
to-head trials at this time” [25]. Its results support the hypoth-
esis that BUD/F is associated with fewer pneumonia events
than FP/S. Apart from the indirect methodology, the authors
advise caution due to heterogeneity, dominance by a single
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study (TORCH), and a lack of predefined diagnostic criteria
for pneumonia.
There have been some small (≤4 weeks) interventional
trials that compared FP/S and BUD/F. These studies are less
clinically meaningful, as they cannot comment on effects on
exacerbations. One study was a 1-week, double-blinded,
cross-over trial (n=442) of FP/S (50/500 μg twice daily
[BD]) vs. BUD/F (320/9μg BD), both by dry-powder inhalers
(DPI). Both short-term treatments were effective, but BUD/F
had a more rapid onset of effect compared with FP/S and
“resulted in greater improvements in ability to perform morn-
ing activities despite the lower inhaled corticosteroid dose”
[26]. A cross-over study of 22 patients investigated adrenal
effect only. Comparing two 4-week treatment arms, no signif-
icant difference was found [27]. There was no wash-out
period before the cross-over.
This year, new observational data were published too. A
10-year matched retrospective cohort, the PATHOS study,
found that fluticasone/salmeterol was worse than
budesonide/formoterol for the risk of pneumonia and pneu-
monia related events in COPD. [28] Jabbar [29] comments on
the study, noting that the event rate “was higher in the
fluticasone/salmeterol group to start with and this was not
adjusted for in the analysis. Differences may be related to
differences in the immunosuppressant potency between
budesonide and fluticasone”. There have been a number of
previous cohort studies. One was a 1-year cohort [30], which
found that BUD/F was significantly less likely to have an
emergency department visit or hospitalisation. Another study
was a retrospective cohort study of US patients. Of 6,770
patients, equally divided, significantly fewer BUD/F patients
had claims for SABAs, but not for LAMAs, COPD-related
outpatient visits, or exacerbations, so that during 6 months
after starting ICS/LABA therapy, there were no differences in
their COPD medical costs [31]. We echo the conclusions of
Blais et al. [30] and Jabbar [29] that long-term clinical trials
are needed to draw certain conclusions and rule out
confounders.
Budesonide/formoterol versus beclometasone/formoterol
There is relatively few data comparing the budesonide/
formoterol combination (DPI) and beclometasone/formoterol
inhalers (which are usually pMDI), probably as both combi-
nations are quite recent.
The previously mentioned Calverley RCT [20] also
contained a BUD/F arm; therefore, it allows us to compare
BUD/F 400/12 μg DPI with BDP/F 200/12 μg pMDI (n=
479). During 48 weeks it showed no significant differences,
with both improving lung function, exacerbation rates, quality
of life, and symptoms, with no safety concerns.
Most recently, a small blinded cross-over RCTof 28 COPD
patients found that after single administration, there was no
difference in the onset of bronchodilation between BDP/F




Comparing fluticasone propionate/salmeterol with
beclometasone/formoterol, there has been one small RCT
(n=18) comparing 12 weeks of FP/S 500/100 μg/day or
BDP/F 400/24 μg/day. BDP/F actually showed a significant
reduction in air trapping and a clinically significant improve-
ment in transition dyspnoea index, which was not seen for FP/
S. BDP/F also showed a significantly greater reduction in
residual lung volume than FP/S [33]. Again, these outcomes
are clinically not very relevant, but hint at how the drugs are
working. This trial was also not powered for adverse events.
However, an observational cross-sectional study in asthma
and COPD found that beclometasone use (not necessarily in
a combination inhaler) was significantly negatively associated
with oropharyngeal side-effects, whereas fluticasone was sig-
nificantly positively associated [34]. We found a completed,
but not yet published, 12-week RCT comparing the same
dosages as Tzani et al. [33] which will hopefully give more
clarity [35].
Fluticasone furoate/vilanterol
Fluticasone furoate (FF) may have a better lung absorp-
tion than fluticasone propionate [36]. A new combination
product, fluticasone furoate/vilanterol (FF/VI), may im-
prove adherence in some patients, as it is the first once-
daily (OD) ICS/LABA and is delivered through a new
DPI device (Ellipta), which is said to be easier to use [37].
Just like the BPD/F inhaler, FF/VI has not been included
yet in the Nannini review [11•]. Examining its effective-
ness over vilanterol alone, therefore, four trials have been
published. Two identical 1-year RCTs (n=around 1,630
each) in moderate to severe COPD of exacerbators, com-
pared VI 25 μg with VI 25 μg combined with FF 200 μg,
100 μg and 50 μg. Their pooled analysis showed a sig-
nificant reduction in exacerbations for all the combination
groups compared to vilanterol alone. However, pneumo-
nia and fractures occurred more commonly, and eight
pneumonia deaths occurred in the FF/VI groups compared
to none in the VI-only group [38]. The publication was
critiqued by Morjaria and Morice [39] for not including
comparison with the standard twice-daily dosing FP/S, the
pre-study ICS use in most participants, including in the
VI-only study arm, and the high findings of pneumonia.
The authors responded that, although difficult, any com-
parisons with FP/S indicate possible reductions in exacer-
bation rates, that ICS use did not affect the outcomes as
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there was no difference in withdrawal rate between groups
during the first month and a persistent effect on exacer-
bations after that, and that the pneumonia rates were
similar to those described with other ICS and still ten
times lower than the reported exacerbation rate [40].
A 24-week RCT of FF/VI (100/25 μg, 50/25 μg) vs.
individual components (FF 100 μg, VI 25 μg) and placebo
was published last year [41]. All active treatments improved
lung function, but there was no significant difference between
FF/VI dosages and VI alone. A trial of the same design, but
with double the FF/VI doses, found the same results [42].
Both trials had no safety concerns with FF/VI over VI. The
year before, two studies had demonstrated FF/VI’s superiority
to placebo [43, 44]. There have also been two 1-week long
safety trials to examine the safety of FF/VI in hepatic and renal
impairment respectively; [45] only in hepatic impairment is
caution advised, as there is a higher risk of systemic cortico-
steroid side-effects.
Fluticasone propionate/salmeterol versus fluticasone
furoate/vilanterol
The first trial comparing fluticasone furoate/vilanterol with
fluticasone propionate/salmeterol, used FF/VI 100/25 μg
OD or FP/S 500/50 μg BD over 12 weeks. Improvements in
lung function and health status were not significantly different
and there was no significant difference in safety profiles [46].
There is a running 12-week study that is evaluating the effects
of FF/VI 100/25 μg against a lower dose FP/S combination
(250/50 μg BD) [47]. A similar trial in asthma has demon-
strated non-inferiority in lung function and safety profile [48].
Ciclesonide and mometasone
Ciclesonide and mometasone are two other ICS that have the
potential for once-daily administration in COPD, due to their
long-acting nature [49, 50]. In both COPD and asthma, how-
ever, these drugs are infrequently prescribed in comparison to
the more familiar ICS [51]. Concerns were raised last year that
ciclesonide seems to be more lipophilic than budesonide in
mice models, which theoretically could increase systemic
adverse events [52]. For mometasone, however, there is a lot
of safety data from asthma [53], justifying its use in a new
combination product.
Mometasone/formoterol
The most recent ICS/LABA combination is mometasone
furoate/formoterol (MF/F), also not yet included in the
Nannini review [11•]. Two 26-week trials of identical design
(total n=2,251) were combined in one analysis before
unblinding of either’s results. It compared MF/F 400/10 μg,
MF/F 200/10 μg, MF 400 μg, F 10 μg, and placebo. There
was significant superiority to placebo onmost outcomes, but it
is more useful to again examine the Nannini review question.
Both MF/F doses showed significantly greater increases in
spirometry than F 10 μg alone throughout the trial. The effect
was four-fold greater withMF/F 400/10μg than with F 10μg.
No difference was found in improvements of symptoms.
There was a 26-week follow-up extension for 75 % of pa-
tients. The incidence of exacerbations was lower in the MF/F
groups, including for severe exacerbations. All arms had few
pneumonia incidences (≤2 %). The rate of adverse events did
not differ significantly over the 26 or 52 weeks [54].
Conclusion of ICS/LABA choice
Because there are insufficient trials of head-to-head compari-
son design, adequate duration (>12 weeks) or with clinically
relevant outcomes, it is currently difficult to recommend any
of ICS/LABA combination over another. As the body of
evidence is largest for the FP/S combination, physicians are
likely to continue to favour this combination. There are indi-
cations in the literature that BUD/F results in less adverse
events, but there is still uncertainty on this issue.
Long-acting anticholinergic combinations
Group D patients: ICS/LABA/LAMA or “Triple therapy”
Adding a LAMA (tiotriopium, TIO; glycopyrronium, GLY; or
aclidinium) to ICS/LABA is called “triple therapy”. GOLD
2013 recommends for group D patients that ICS be combined
with LABA or LAMA, “with some evidence for triple thera-
py”. Indeed, a 2011 Cochrane review [55] only found three
studies, and had low confidence in drawing any conclusions
for the outcomes as a result of heterogeneity and wide confi-
dence intervals, except for an improvement of quality of life
scores and lung function for triple therapy versus TIO alone.
Only one small study also examined our clinically relevant
question of triple therapy versus ICS/LABA, which was in-
sufficient to draw firm conclusions.
Since the review, there have been a few new trials. Hanania
et al. [56] was a 24-week, double-blinded RCT (n=342) of
TIO (18 μg OD) versus triple therapy (FP/S 250/50 μg
DISKUS BD and TIO). Triple therapy improved lung func-
tion and reduced rescue inhaler use. Unlike some of its pre-
decessors, there was no difference in exacerbations either. The
adverse event profile was also similar. A similar trial of the
same length and doses (n=479) also found triple therapy to be
superior in lung function, and in quality of life. This study,
however, was open-label; the lack of blinding reduces our
confidence in its results [57]. A smaller, 8-week RCT found
no difference in exercise tolerance between triple therapy (FP/
S/TIO) compared to TIO alone [58], but this study is less
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clinically relevant as it is too short to comment on outcomes
such as exacerbations.
Two future studies have been identified, both using GLY
instead of TIO, and comparing to triple therapy involving
BDP/F. [59, 60] They plan to publish in 2016. The Singh
study will investigate our clinically relevant question of BDP/
F/GLYvs. BDP/F.
Loke and Singh [61] describe how concerns over cardio-
vascular events and mortality have existed around TIO for a
while now, especially around the Respimat inhaler. They have
not entirely been alleviated by the UPLIFT trial, since there
has been new, observational data raising more concerns re-
garding urinary retention. Compared with the TIO
HandiHaler, “some experts have argued that there is no com-
pelling reason to choose the Respimat formulation” [61]. This
may be why attention is turning to GLY instead. Meanwhile, a
3–year, multinational trial is seeking to answer the questions
around Respimat once and for all [62].
LABA/LAMA versus ICS/LABA
We have mainly examined comparisons of the first choice
column of the GOLD recommendations. Other comparisons
(e.g. involving ICS/LAMA) have been less addressed in the
literature, but may become commercially relevant to investi-
gate once a company devises a new fixed combination. This
could alter the GOLD first choice recommendations in the
future. One such new fixed combination is a LABA/LAMA:
indacaterol with glycopyrronium, also known as “QVA149”.
Indacaterol is a new once-daily LABA that has recently been
reviewed by Ribeiro and Chapman [63].
The ILLUMINATE trial investigated QVA149 110/50 μg
OD versus FP/S 50/500 μg BD over 26 weeks (n=253). They
found significant improvements in lung function and some
symptom outcomes. The lack of pneumonia events (vs. four in
FP/S) and less adverse events, including exacerbations and
withdrawal, seem the most promising results for future inves-
tigation [64]. This was a trial of stage 2 and 3 COPD patients
with less than two exacerbations in the previous year.
Other new LABA/LAMA fixed combinations in develop-
ment or awaiting regulatory approval are: vilanterol/
umeclidinium, olodaterol/tiotropium, and BD formoterol/
aclidinium [65].
Inhalers
We have not yet addressed any questions regarding which
inhalers to choose. A new study challenged the previous
evidence that a fixed combination inhaler is better for compli-
ance than single inhalers, finding no difference [66]. The
authors caution that this may have only been because their
trial population is rigorously trained, and may not reflect real-
life. It does raise the possibility of not being restricted to only
the fixed combination inhalers we have examined in this
paper.
Clinicians may also wonder whether the type of inhaler
makes any difference. In most European countries, the fol-
lowing inhalers are available for ICS/LABA: pMDIs and
various DPIs (Aerolizer, Turbuhaler, Diskus). When looking
at separate inhalers, for LABA or ICS, there's also the
Novolizer DPI and nebulisers, and for ICS only, there is the
additional Autohaler (breath-actuated pMDI) [67, 68].
Nebulisers are reserved for emergencies, or patients who
cannot handle a pocket-sized device [67]. There has been a
flurry of new DPI inhalers because of patent mortality [69],
and because it is felt the pMDIs have many limitations [70].
One such new DPI device is the Rotahaler, which is currently
being trialled [71]. There have been RCTs trying to establish
the efficacy of MDIs over DPIs because of their relative
advantages, however, including an FP/S MDI [72]. The rela-
tive advantages and disadvantages of pMDIs compared to
DPIs are summarised in Table 2.
RCT comparing inhaler devices are scarce and systematic
reviews have found no difference in clinical efficacy [67].
These are, however, limited in generalisability to real-life
situations, as only patients able to correctly use these inhalers,
are selected for RCTs [67]. Decision-making should, there-
fore, involve a range of different factors, including: the indi-
vidual patient; price and availability; similarity to other in-
halers the patient uses; ability for the health carer to correctly
train the patient; ability of the patient to handle the inhaler;
patient preference [67].
Exacerbations of COPD: systemic steroids
For COPD acute exacerbations, the GOLD treatment remains
respiratory support, SABAwith or without SAMA, systemic
steroids, and antibiotics if a bacterial infection is suspected.
Prednisolone 30 – 40mg per day for 10 – 14 days is suggested
by GOLD; [1•] however, evidence has changed over the last
year to favouring a 5-day course. The REDUCE trial (n=296)
showed that 5 days of 40 mg of prednisolone was non-inferior
to 14 days, with no difference in time to first exacerbation
within 6 months, mortality, recovery of lung function, or
treatment-related adverse events [73•]. This trial will help
standardise steroid regimens, and reduce cumulative exposure
and risk of toxicity for frequent exacerbators [74]. Another
trial last year investigated whether intravenous (IV) treatment
was better than methylprednisolone taken orally, but found the
reverse [75], following on from a trial showing superiority of
IV methylprednisolone over IV hydrocortisone in lung func-
tion only, but not recurrence of exacerbations [76].
The REDUCE trial highlighted the poor prognosis of
COPD exacerbation, even when treated with steroids, and
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the need to find new management options [74]. One such
option was etanercept (a tumour necrosis factor α [TNFα]
antagonist), but a small clinical trial, limited by its short time-
to-follow-up, found it was not more effective than prednisone
in the treatment of exacerbations [77].
Meanwhile, GOLD suggests nebulised budesonide as
an alternative [1•]. Indeed a non-blinded trial of 86
hospitalised patients compared nebulised budesonide of
2 mg and of 4 mg (BD) with IV methylprednisolone
40 mg up until discharge and found no difference between
the groups in spirometry or arterial blood gas samples
[78], but this finding requires further study before clinical
use.
In an intensive care (ICU) setting, last year, a pairwise,
retrospective, case-control matching study (n=32) of exacer-
bating patients requiring mechanical ventilation or ICU found
that steroids taken orally reduced the time of mechanical
ventilation [79], whereas for severe exacerbations, a
randomised evaluation showed that prednisone did not im-
prove ICU mortality or patient-centred outcomes. It signifi-
cantly increased the risk of hyperglycaemia [80]. Lastly, a new
large cohort study (n=17,239) suggested that there may be
benefits to using low doses of methylprednisolone (<240 mg/
day) over higher regimens, but randomised trials are needed to
confirm this [81].
Corticosteroid responsiveness
There is still a concern about a significant group of COPD
patients that are less steroid-responsive. Papers last year
suggested that steroid resistance could be reversed using
theophylline, phosphoinositide 3-kinase δ inhibitors, or
LABAs [82], using adjunctive adenosine A2B-receptor
agonist therapy [83], using cyclosporin or CRAC channel
inhibitor Synta 66 [84], the novel macrolide solithromycin
[85], a p38 mitogen inhibitor [86], or PDE4 inhibitors
[87, 88]. However, these results remain on the research
agenda and have no clinical implications yet.
Steroid withdrawal
With questions surrounding the effectiveness of steroids in
COPD, withdrawal trials have been performed in the past to
evaluate whether patients treated with ICS, fared better with-
out them. A 2011 systematic review of such trials found no
evidence that withdrawing patients resulted in important de-
terioration in outcomes in practice [89]. A protocol was pub-
lished this year for a big study addressing this issue. The
WISDOM study (n=2,456) will investigate stepwise steroid
withdrawal versus continuation of treatment in GOLD stage 3
and 4 patients who are exacerbators, with as primary outcome
the first exacerbation up to 52 weeks [90].
Heterogeneity of COPD
The GOLD guidelines moved away in 2011 from purely lung-
function measurements as a method of predicting response to
treatment, to a more phenotypic classification of COPD
groups, by introducing exacerbation risk and mMRC or
CAT scores (and later CCQ). Recently, researchers have
started going back to exploring splitting COPD into several
different phenotypes [91, 92]. Not all of these phenotypes are
clinically useful at the moment, and there is a lack of big
studies validating them or testing different treatment regimes.
Exceptions have included Rennard [93] and Albert. [94] Sev-
eral countries’ COPD guidelines have already tried to account
for some phenotypes where we have evidence that a different
pharmacological management is beneficial, including
Canada’s 2007 guidelines [95], Japan [96], and Spain [97].
Miravitlles et al. [92] suggest four clinically relevant pheno-
types: infrequent exacerbators, frequent exacerbators with
either emphysema or chronic bronchitis separately, and a
COPD-asthma overlap type. Of these, except for the first
group, all are amenable to ICS. For exacerbations, based on
Bafadhel et al. [98], they suggest distinguishing non-
eosinophilic exacerbators from eosinophilic, which improve
on systemic steroid, as opposed to the former group which
Table 2 Advantages and disadvantages of MDIs and DPIs
MDI DPI
Good hand-breath coordination required (except for breath-actuated
Autohaler) [68]
No need for coordination of inhalation and actuation [70]
Addition of spacer does not completely fix this Does not require a spacer [70]
May be unsuitable for elderly, confused, or patients with hand
rheumatologic conditions
Easier to use than MDI [67, 70]
Suitable for tracheostomy, intubation [72] Breath-actuation difficult in patients with low inspiratory effort (hyperinflation,
muscular weakness) [67]
Concerns about HFA-propellant environmental friendliness [72] Lactose carrier: contra-indicated in lactose allergy [68, 72]
Drugs may settle (shake before use) [68]
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may worsen on steroids compared to placebo. Bafadhel et al.
[98] is a 2-week, double-blind interventional trial, where there
was a significantly greater improvement in the chronic respi-
ratory questionnaire (CRQ) of patients with exacerbations that
were eosinophilic-negative and treated with placebo than if
treated with prednisolone. There was also a significant in-
crease in treatment failures on prednisolone than placebo.
Also, there was no significant difference in CRQ of patients
that were treated based on eosinophils compared to the pa-
tients that were treated without eosinophilic guidance, while it
reduced the likelihood of being treated with prednisolone by
half. However, the authors themselves recognise that larger
studies are needed [98]. This evidence would suggest that this
classification is not ready for use in clinical practice yet.
It is likely that, in future, the GOLD guidelines will adjust
even more to account for different phenotypes. Meanwhile,
more research into associated genes has identified further
groups [91], bringing individualised therapy based on genetic
phenotyping closer to reality [99].
Conclusion
New GOLD guidelines take into account exacerbation risk
and quality of life scores. It is possible that, in future, COPD
phenotypes will be sub-divided further. ICS are only recom-
mended in combination with a LABA and/or LAMA. The
type of ICS chosen should be carefully considered based on
the patient’s need for a reduction in exacerbations, balanced
against the risk of pneumonia. More head-to-head trials are
needed. However, such trials are unlikely due to both the
sample size and length that would be needed to show a
difference in effect, and the lack of commercial incentive for
investing in such trials. The type of inhaler should be chosen
based on the individual patient’s needs and preferences. For
exacerbations of COPD, systemic steroids should now only be
given for 5 days instead of 10 – 14 days, but more research is
needed into alternative therapies.
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